X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5380) 5380
Publication (413) 413
Book Review (42) 42
Magazine Article (8) 8
Book Chapter (4) 4
Conference Proceeding (4) 4
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5260) 5260
female (3648) 3648
middle aged (3447) 3447
oncology (3319) 3319
aged (3122) 3122
taxoids - administration & dosage (2957) 2957
index medicus (2807) 2807
docetaxel (2768) 2768
male (2719) 2719
antineoplastic combined chemotherapy protocols - therapeutic use (2567) 2567
adult (2519) 2519
chemotherapy (2379) 2379
taxoids - adverse effects (2048) 2048
antineoplastic combined chemotherapy protocols - adverse effects (1919) 1919
treatment outcome (1748) 1748
cancer (1659) 1659
breast neoplasms - drug therapy (1582) 1582
taxoids - therapeutic use (1419) 1419
paclitaxel (1064) 1064
drug administration schedule (942) 942
taxoids (899) 899
breast cancer (883) 883
disease-free survival (873) 873
aged, 80 and over (857) 857
lung neoplasms - drug therapy (852) 852
antineoplastic agents - adverse effects (815) 815
neoplasm staging (815) 815
care and treatment (809) 809
antineoplastic agents - therapeutic use (799) 799
breast neoplasms - pathology (798) 798
cisplatin - administration & dosage (786) 786
cisplatin (771) 771
pharmacology & pharmacy (764) 764
trial (764) 764
paclitaxel - analogs & derivatives (762) 762
paclitaxel - administration & dosage (755) 755
paclitaxel - adverse effects (735) 735
carcinoma, non-small-cell lung - drug therapy (731) 731
medicine & public health (727) 727
antineoplastic combined chemotherapy protocols - administration & dosage (719) 719
therapy (705) 705
deoxycytidine - analogs & derivatives (668) 668
fluorouracil - administration & dosage (634) 634
antineoplastic agents, phytogenic - adverse effects (591) 591
survival rate (571) 571
neoplasm metastasis (569) 569
survival analysis (564) 564
deoxycytidine - administration & dosage (558) 558
research (549) 549
antineoplastic agents - administration & dosage (548) 548
antineoplastic agents (535) 535
dose-response relationship, drug (525) 525
metastasis (522) 522
retrospective studies (521) 521
carcinoma (511) 511
survival (509) 509
hematology, oncology and palliative medicine (495) 495
prostatic neoplasms - drug therapy (492) 492
prostate cancer (491) 491
antimitotic agents (490) 490
antineoplastic agents, phytogenic - therapeutic use (478) 478
neutropenia - chemically induced (471) 471
clinical trials (439) 439
drug therapy (438) 438
paclitaxel - therapeutic use (421) 421
lung neoplasms - pathology (420) 420
disease progression (419) 419
combination (416) 416
analysis (415) 415
phase-ii trial (408) 408
prognosis (407) 407
antineoplastic agents, phytogenic - administration & dosage (405) 405
animals (397) 397
doxorubicin (392) 392
gemcitabine (387) 387
adenocarcinoma - drug therapy (384) 384
chemotherapy, adjuvant (374) 374
cancer research (366) 366
carcinoma, non-small-cell lung - pathology (366) 366
neoplasms - drug therapy (365) 365
cisplatin - adverse effects (359) 359
capecitabine (353) 353
kaplan-meier estimate (352) 352
follow-up studies (351) 351
fluorouracil (349) 349
drug resistance, neoplasm (347) 347
toxicity (347) 347
infusions, intravenous (341) 341
combined modality therapy (340) 340
carboplatin (332) 332
stomach neoplasms - drug therapy (330) 330
radiotherapy (327) 327
cyclophosphamide - administration & dosage (318) 318
prospective studies (316) 316
quality of life (311) 311
oncology, experimental (307) 307
deoxycytidine - adverse effects (306) 306
fluorouracil - adverse effects (305) 305
pharmacology/toxicology (302) 302
carboplatin - administration & dosage (300) 300
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4973) 4973
Japanese (187) 187
Chinese (64) 64
French (52) 52
German (51) 51
Russian (18) 18
Italian (13) 13
Spanish (13) 13
Hungarian (8) 8
Polish (3) 3
Danish (2) 2
Lithuanian (2) 2
Czech (1) 1
Dutch (1) 1
Korean (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Supportive Care in Cancer, ISSN 0941-4355, 5/2019, Volume 27, Issue 5, pp. 1919 - 1925
Journal Article
Journal Article
Journal Article
Bioorganic Chemistry, ISSN 0045-2068, 03/2019, Volume 83, pp. 154 - 160
Docetaxel is one of the most effective anticancer drugs. However, the current formulation of docetaxel contains Tween 80 and ethanol as the solvent, which can... 
Conjugate | 6-Maleimidocaproic acid | Human serum albumin (HSA) | Docetaxel | ACID | EFFICACY | HUMAN SERUM-ALBUMIN | BIOCHEMISTRY & MOLECULAR BIOLOGY | TAXOIDS | CHEMISTRY, ORGANIC | PACLITAXEL | BREAST-CANCER | NANOPARTICLES | DRUG CARRIER | PRODRUG | DERIVATIVES | Antimitotic agents | Cysteine | Hydroxides | Surface active agents | Albumin | Antineoplastic agents | Prostate cancer
Journal Article
Drug Design, Development and Therapy, ISSN 1177-8881, 2019, Volume 13, pp. 539 - 553
Purpose: Fluoropyrimidine plus platinum (FP) is currently the standard treatment for esophageal cancer (EC). In recent years, taxane-based chemotherapy has... 
Clinical cancer research | Digestive cancer | Chemotherapy | Survival | CONCURRENT CISPLATIN | CHEMISTRY, MEDICINAL | survival | PHASE-II | CHEMORADIOTHERAPY | FLUOROURACIL | chemotherapy | DOCETAXEL | clinical cancer research | PACLITAXEL | 5-FLUOROURACIL | digestive cancer | NEOADJUVANT CHEMOTHERAPY | SQUAMOUS-CELL CARCINOMA | CHEMORADIATION | PHARMACOLOGY & PHARMACY | Taxoids - therapeutic use | Bridged-Ring Compounds - therapeutic use | Antineoplastic Agents - adverse effects | Pyrimidines - therapeutic use | Humans | Bridged-Ring Compounds - adverse effects | Antineoplastic Agents - therapeutic use | Esophageal Neoplasms - drug therapy | Organoplatinum Compounds - therapeutic use | Taxoids - adverse effects | Squamous cell carcinoma | Cell survival | Effectiveness | Leukopenia | Toxicity | Medical services | Diarrhea | Taxane | Disease control | Patients | Subgroups | Esophagus | Platinum | Esophageal cancer | Cancer | Neutropenia | Oncology | Systematic review | Metastasis | Cancer therapies | Quality | Surgery | Meta-analysis | Studies | Medical prognosis | Health risk assessment | Pharmaceutical Sciences | Basic Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Farmaceutiska vetenskaper | Klinisk medicin | Clinical Medicine | Medicinska och farmaceutiska grundvetenskaper | Cancer and Oncology | Cancer och onkologi
Journal Article
Gan to kagaku ryoho. Cancer & chemotherapy, ISSN 0385-0684, 02/2019, Volume 46, Issue 2, p. 279
Prophylaxis using pegfilgrastim is recommended to prevent cabazitaxel-induced neutropenia. We observed GradeB3 neutropenia in a patient after administration of... 
Antineoplastic Agents - adverse effects | Humans | Risk Factors | Granulocyte Colony-Stimulating Factor | Filgrastim - therapeutic use | Retrospective Studies | Neutropenia - chemically induced | Polyethylene Glycols - therapeutic use | Taxoids - adverse effects
Journal Article
Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina, 02/2019, Volume 16, Issue 1, p. 77
Aim To compare the effect of neoadjuvant chemotherapy based on taxane and/or anthracycline to the extent of an objective response in female patients with... 
Taxoids - therapeutic use | Bridged-Ring Compounds - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Humans | Female | Neoadjuvant Therapy | Treatment Outcome | Antineoplastic Agents - therapeutic use | Anthracyclines - therapeutic use | Breast Neoplasms - drug therapy
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 01/2019, Volume 116, Issue 5, pp. 1698 - 1703
Although chemotherapy is a conventional cancer treatment, it may induce a protumorigenic microenvironment by triggering the release of proinflammatory... 
Cyclooxygenase | Inflammation | Debris | Soluble epoxide hydrolase | Oxylipins | CYCLOOXYGENASE-2 | CELL REPOPULATION | MULTIDISCIPLINARY SCIENCES | BONE-MARROW | cyclooxygenase | soluble epoxide hydrolase | TISSUE-LEVELS INCREASE | PROMETASTATIC FACTORS | inflammation | THERAPEUTIC TARGET | debris | oxylipins | BIOACTIVE LIPIDS | TUMOR-GROWTH | RECEPTIVE MICROENVIRONMENT | Taxoids - pharmacology | Lipids | Inflammation - metabolism | Carcinoma, Ovarian Epithelial - drug therapy | Antineoplastic Agents - adverse effects | Inflammation - drug therapy | Bridged-Ring Compounds - pharmacology | Female | Antineoplastic Agents - pharmacology | Ovarian Neoplasms - metabolism | Ovarian Neoplasms - drug therapy | Platinum - pharmacology | Disease Models, Animal | Cyclooxygenase 2 Inhibitors - pharmacology | Cytokines - metabolism | Mice, Inbred C57BL | Carcinoma, Ovarian Epithelial - metabolism | Mice, SCID | Disease Progression | Macrophages - metabolism | Animals | Signal Transduction - drug effects | Cyclooxygenase 2 - metabolism | Macrophages - drug effects | Cell Proliferation - drug effects | Mice | Epoxide Hydrolases - antagonists & inhibitors | Chemotherapy | Control | Care and treatment | Cytokines | Physiological aspects | Dosage and administration | Nonsteroidal anti-inflammatory drugs | Methods | Ovarian cancer | Cancer | Animal models | Ovarian carcinoma | Detritus | Pharmacology | Taxane | Macrophages | Epoxide hydrolase | Prostaglandin endoperoxide synthase | Inhibitors | Platinum | Cyclooxygenase-2 | Staphylococcal enterotoxin H | Ascites | Tumors | Biological Sciences
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 4/2018, Volume 168, Issue 3, pp. 625 - 630
Journal Article
Clinical Genitourinary Cancer, ISSN 1558-7673, 12/2018, Volume 16, Issue 6, pp. 458 - 465.e2
Journal Article
Cancer communications (London, England), ISSN 2523-3548, 05/2018, Volume 38, Issue 1, pp. 21 - 10
Journal Article